Your browser doesn't support javascript.
loading
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
Srivastava, Abhishek K; Dinc, Gunes; Sharma, Rajesh K; Yolcu, Esma S; Zhao, Hong; Shirwan, Haval.
Afiliación
  • Srivastava AK; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
  • Dinc G; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
  • Sharma RK; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
  • Yolcu ES; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
  • Zhao H; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
  • Shirwan H; Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky. haval.shirwan@louisville.edu.
Cancer Res ; 74(22): 6441-51, 2014 Nov 15.
Article en En | MEDLINE | ID: mdl-25252915

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Vacunas contra el Cáncer / Estreptavidina / Ligando 4-1BB / Lípido A Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cancer Res Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Vacunas contra el Cáncer / Estreptavidina / Ligando 4-1BB / Lípido A Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cancer Res Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos